Surmodics (Nasdaq:SRDX) today announced the successful early clinical use of its Pounce XL thrombectomy system.

Few procedures have gone through a decade of practice-changing clinical trials as impressive as thrombectomy for stroke. Beginning in 2015 with multiple trials showing a benefit with thrombectomy ...

The median mRS score at that time point was 2 in both groups. None of the secondary outcomes favored thrombectomy. In terms of safety, the procedure was associated with higher rates of 90-day ...

Surmodics Pounce Thrombectomy systems are intended for the non-surgical removal of thrombi ... the need for hospitalizations and follow-up procedures.” About the Pounce Thrombectomy Platform ...

Surmodics, Inc. announced the early clinical use of its Pounce XL thrombectomy system, which is currently in limited market rel ...

The hospital's state-of-the-art American Heart and Vascular Institute performed a challenging surgery including open ...

"One of the biggest challenges in thrombectomy procedures for PE is determining when you've successfully removed the thrombus entirely, as incomplete removal can may lead to suboptimal outcomes ...

Akura Medical has enrolled the first subject in the multi-centre QUADRA-PE trial, which is assessing its flagship Katana thrombectomy system in treating acute pulmonary embolism (PE) patients.

Penumbra recently announced the launch of the Lightning Bolt 12 and the Lightning Bolt 6X with Trax systems, the next generatio ...

"With this trial, the hope is to provide physicians with continuous, real-time pulmonary artery pressure readings throughout the entire procedure to streamline the removal of the blood clot." "One of ...